Nuon examine confirms hidden utility of tranilast as uricosuric cause
Nuon Therapeutics, Inc., a privately held, clinical concoct biopharmaceutical ensemble, announced today that results from clinical and preclinical studies demonstrating the faculty of tranilast to turn serum uric acid levels and monosodium urate crystal-induced infection – two signal chance factors quest of gout – were presented at The European Federated with Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology in Rome, Italy, June 16-19, 2010.
“These results substantiate the future utility of tranilast as a uricosuric spokesperson while also demonstrating its anti-inflammatory project that may offer additional therapeutical forward in the treatment of gout”
Tranilast is an anti-inflammatory vehicle at developed in Japan, which is marketed in Asia recompense asthma, allergic rhinitis, atopic dermatitis and hypertrophic scarring. Nuon Pharmaceuticals, tipsy a permit from Kissei Pharmaceutical Co., Ltd., is currently studying the parasynthetic, in syndication with allopurinol, in its hero program in gout, NU1618.
"These results settle the imminent utility of tranilast as a uricosuric factor while also demonstrating its anti-inflammatory project that may anticipate additional beneficial service perquisites in the treatment of gout," said Lee Rauch, president and chief managing director apparatchik of Nuon Therapeutics. "Validating earlier clinical observations on touching tranilast, this check in was the heart suited for our arbitration to set ones cap for our NU1618 program, which we arrange instanter advanced into step 2b clinical progress in hyperuricemia and gout."
Tranilast Reduces Serum Uric Acid Rsum #SAT 0369)
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
